MeSH term
Frequency | Condition_Probility | Female | 20 | 0.0 |
Humans | 55 | 0.0 |
Male | 30 | 0.0 |
Research Support, Non-U.S. Gov't | 20 | 0.0 |
Trihexosylceramides/urine | 2 | 100.0 |
Reproducibility of Results | 3 | 0.0 |
Animals | 10 | 0.0 |
Mice | 3 | 0.0 |
Body Weight/drug effects | 2 | 1.0 |
Caco-2 Cells | 3 | 0.0 |
Chromatography, High Pressure Liquid | 6 | 0.0 |
Micelles | 2 | 4.0 |
Organ Size/drug effects | 2 | 2.0 |
Rats | 5 | 0.0 |
Rats, Wistar | 3 | 0.0 |
Adolescent | 8 | 0.0 |
Adult | 13 | 0.0 |
Middle Aged | 15 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 8 | 0.0 |
Cholesterol/*metabolism | 2 | 0.0 |
Soybean Proteins/chemistry/*pharmacology | 2 | 100.0 |
Molecular Sequence Data | 3 | 0.0 |
Antimetabolites, Antineoplastic/*blood | 2 | 100.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
Methotrexate/*blood | 2 | 66.0 |
Child | 8 | 0.0 |
Child, Preschool | 7 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Cystathionine gamma-Lyase/*genetics | 2 | 100.0 |
Comparative Study | 7 | 0.0 |
Glycosphingolipids/*analysis | 2 | 40.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Aged | 6 | 0.0 |
Chronic Disease | 6 | 0.0 |
English Abstract | 9 | 0.0 |
Infant | 4 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Leukocytes/enzymology | 2 | 1.0 |
Cell Line | 6 | 0.0 |
Chromatography, Thin Layer | 3 | 1.0 |
Kinetics | 2 | 0.0 |
Ceramides/analysis | 3 | 50.0 |
Cells, Cultured | 2 | 0.0 |
Glycolipids/isolation & purification | 2 | 66.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Glycolipids/analysis | 2 | 16.0 |
Microscopy, Electron | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
*Trihexosylceramides | 2 | 100.0 |
Blood Group Antigens/*immunology | 2 | 6.0 |
P Blood-Group System/*immunology | 2 | 100.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Erythrocytes/analysis | 2 | 8.0 |
Follicle Stimulating Hormone/blood | 2 | 0.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Testosterone/blood | 2 | 0.0 |
Carbohydrates/analysis | 2 | 3.0 |
